Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Salarius Pharmaceuticals ( (SLRX) ) has issued an announcement.
On July 8, 2025, Salarius Pharmaceuticals held a special meeting of stockholders where they approved several proposals. The key decisions included a reverse stock split of the company’s common stock and the issuance of shares to comply with Nasdaq listing rules. These approvals are significant for the company’s strategic financial management and compliance with stock exchange requirements.
Spark’s Take on SLRX Stock
According to Spark, TipRanks’ AI Analyst, SLRX is a Underperform.
Salarius Pharmaceuticals exhibits significant financial instability, characterized by declining revenues and persistent losses, which severely impacts its stock score. Technically, the stock is on a bearish trend, trading below major moving averages, with negative momentum indicators. The valuation is further weakened by a negative P/E ratio and absence of dividend, making it unattractive to value or income investors. Overall, the stock is highly risky and requires cautious consideration.
To see Spark’s full report on SLRX stock, click here.
More about Salarius Pharmaceuticals
Salarius Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on developing cancer therapies. The company is involved in creating innovative treatments to address unmet medical needs in oncology.
Average Trading Volume: 1,222,834
Technical Sentiment Signal: Strong Sell
Current Market Cap: $1.76M
See more data about SLRX stock on TipRanks’ Stock Analysis page.